Companies › Orchard Therapeutics
3 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OTL-203 Autologous CD34+ enriched hematopoietic stem and progenitor cells transduced with lentivir | – | Phase 3 | MPS-IH (Hurler Syndrome) | Mar 2028 |
| Atidarsagene Autotemcel (OTL-200) ARSA exogenous gene | ARSA | Phase 3 | Lysosomal Storage Diseases | Mar 2031 |
| Autologous CD34+ hematopoietic stem and progenitor cells genetically modified wi Lentiviral vector-mediated gene therapy delivering human α-L-iduronidase (IDUA) cDNA to au | IDUA | Phase 1 | Mucopolysaccharidosis IH | Jan 2035 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06149403 | OTL-203 | Phase 3 | MPS-IH (Hurler Syndrome) | Metabolic and endocrine | Mar 2028 |
| NCT04283227 | Atidarsagene Autotemcel (OTL-200) | Phase 3 | Lysosomal Storage Diseases | Metabolic and endocrine | Mar 2031 |
| NCT03488394 | Autologous CD34+ hematopoietic stem and progenitor cells genetically modified wi | Phase 1 | Mucopolysaccharidosis IH | Metabolic and endocrine | Jan 2035 |
Spur Therapeutics iECURE Yong Zhao, MD, PhD Estar Medical dba Medical Technologies Wellizen Australia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.